Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shield Therapeutics ( (GB:STX) ) just unveiled an update.
Shield Therapeutics has successfully raised £1.5 million through a placing of new ordinary shares, driven by unsolicited institutional investor demand, to support the growth of its leading product, ACCRUFeR®, in the U.S. market. This financial move, which involved issuing shares at a premium, aims to strengthen the company’s working capital and broaden its shareholder base, positioning Shield to accelerate sales and achieve positive cash flow by the end of 2025.
The most recent analyst rating on (GB:STX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on GB:STX Stock
According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical performance, indicating strong market momentum. However, significant financial weaknesses, including negative profitability and cash flow issues, weigh heavily on the score. Valuation concerns due to a negative P/E ratio and lack of dividend yield further impact the stock’s attractiveness.
To see Spark’s full report on GB:STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focusing on the treatment of iron deficiency with its innovative product, ACCRUFeR®/FeRACCRU® (ferric maltol). The company operates in the U.S. through a collaboration with Viatris and has licensed its product to various pharmaceutical companies globally, including in Europe, China, and Japan. ACCRUFeR® is the first FDA-approved oral iron therapy for iron deficiency and anemia, addressing a significant unmet medical need.
Average Trading Volume: 3,698,271
Technical Sentiment Signal: Hold
Current Market Cap: £93.75M
See more insights into STX stock on TipRanks’ Stock Analysis page.